Randomized placebo controlled single blind study of the effectiveness of ACOTIAMIDE in functional dyspepsia

Payel Chakraborty0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•1.Patient with abnormal upper GI endoscopy.
•2. Patient with alarm features (unintentional weight loss, persistent vomiting, dysphagia, hematemesis, melena, fever,
•jaundice, or anemia),
•3. Recent gastrointestinal surgery i.e. within 30 days.
•4. Patients who show any of the following values at the baseline laboratory tests: severe anaemia, total leukocyte count <
•, platelet count < 75,000/mm3
•, AST and ALT Ã¢â?°Â¥ 100 IU/L, Creatinine Ã¢â?°Â¥ 1.5 mg/dL The blood tests should
•have been done not more than 4 weeks prior to enrollment.
•5.Treatment with non-steroidal anti-inflammatory drugs (NSAIDs), H2-blockers, proton pump inhibitors, prokinetic
•agents, misoprostol or sucralfate 15 days prior to enrollment.
•6. Concomitant serious disease of vital organs such as the liver, kidney, heart or lungs.
•7.History of hypersensitivity to either of the study drugs or closely allied drugs.
•8. Women who are pregnant, lactating, or not willing to use adequate methods of contraception.
•9.Any other condition which can lead the study investigators to consider the subject unsuitable for selection.

发起方

Payel Chakraborty